Cargando…
Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers
Patients with COVID-19 present a broad spectrum of clinical presentation. Whereas hypoxaemia is the marker of severity, different strategies of management should be customised to five specific individual phenotypes. Many intubated patients present with phenotype 4, characterised by pulmonary hypoxic...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236837/ https://www.ncbi.nlm.nih.gov/pubmed/32341111 http://dx.doi.org/10.1183/13993003.01028-2020 |
_version_ | 1783536221512794112 |
---|---|
author | Rello, Jordi Storti, Enrico Belliato, Mirko Serrano, Ricardo |
author_facet | Rello, Jordi Storti, Enrico Belliato, Mirko Serrano, Ricardo |
author_sort | Rello, Jordi |
collection | PubMed |
description | Patients with COVID-19 present a broad spectrum of clinical presentation. Whereas hypoxaemia is the marker of severity, different strategies of management should be customised to five specific individual phenotypes. Many intubated patients present with phenotype 4, characterised by pulmonary hypoxic vasoconstriction, being associated with severe hypoxaemia with “normal” (>40 mL·cmH(2)O(−1)) lung compliance and likely representing pulmonary microvascular thrombosis. Phenotype 5 is often associated with high plasma procalcitonin and has low pulmonary compliance, Which is a result of co-infection or acute lung injury after noninvasive ventilation. Identifying these clinical phenotypes and applying a personalised approach would benefit the optimisation of therapies and improve outcomes. |
format | Online Article Text |
id | pubmed-7236837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-72368372020-06-03 Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers Rello, Jordi Storti, Enrico Belliato, Mirko Serrano, Ricardo Eur Respir J Perspective Patients with COVID-19 present a broad spectrum of clinical presentation. Whereas hypoxaemia is the marker of severity, different strategies of management should be customised to five specific individual phenotypes. Many intubated patients present with phenotype 4, characterised by pulmonary hypoxic vasoconstriction, being associated with severe hypoxaemia with “normal” (>40 mL·cmH(2)O(−1)) lung compliance and likely representing pulmonary microvascular thrombosis. Phenotype 5 is often associated with high plasma procalcitonin and has low pulmonary compliance, Which is a result of co-infection or acute lung injury after noninvasive ventilation. Identifying these clinical phenotypes and applying a personalised approach would benefit the optimisation of therapies and improve outcomes. European Respiratory Society 2020-05-21 /pmc/articles/PMC7236837/ /pubmed/32341111 http://dx.doi.org/10.1183/13993003.01028-2020 Text en Copyright ©ERS 2020 http://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Perspective Rello, Jordi Storti, Enrico Belliato, Mirko Serrano, Ricardo Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers |
title | Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers |
title_full | Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers |
title_fullStr | Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers |
title_full_unstemmed | Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers |
title_short | Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers |
title_sort | clinical phenotypes of sars-cov-2: implications for clinicians and researchers |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236837/ https://www.ncbi.nlm.nih.gov/pubmed/32341111 http://dx.doi.org/10.1183/13993003.01028-2020 |
work_keys_str_mv | AT rellojordi clinicalphenotypesofsarscov2implicationsforcliniciansandresearchers AT stortienrico clinicalphenotypesofsarscov2implicationsforcliniciansandresearchers AT belliatomirko clinicalphenotypesofsarscov2implicationsforcliniciansandresearchers AT serranoricardo clinicalphenotypesofsarscov2implicationsforcliniciansandresearchers |